Search Results
Your search for all items matches 34705 pages
Showing 27951 - 28000FDA Grants Volasertib Breakthrough Therapy Designation in AML
Boehringer Ingelheim Pharmaceuticals, Inc, has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to volasertib, an investigational inhibitor of polo-like kinase (Plk), which being evaluated for the treatment of patients aged 65 or older with...
ASCO Develops Educational Article Series on Research Funding
During this and the coming year, ASCO is ramping up its advocacy efforts in calling for increased federal funding to support clinical cancer trials. As part of an extensive effort to educate and mobilize its membership to call for a renewed national investment in federally funded cancer research,...
Zhe-Bin Liu, MD, PhD, of China Receives 2013 Long-Term International Fellowship in Breast Cancer
Zhe-Bin Liu, MD, PhD, of Shanghai Cancer Center, Fudan University, China, is the recipient of the 2013 Conquer Cancer Foundation of ASCO Long-Term International Fellowship (LIFe) in Breast Cancer, generously supported by The Breast Cancer Research Foundation. The LIFe provides early-career...
ASCO Submits Comments on Numerous Federal Initiatives
ASCO helps shape the regulatory framework in which oncologists practice by reviewing and commenting on a wide range of rules, guidelines, and system changes issued by federal agencies, including the U.S. Food and Drug Administration (FDA), the Centers for Medicare and Medicaid Services (CMS), and...
Highlights on Quality Cancer Care for Patients
In advance of the 2013 Quality Care Symposium, ASCO released a second Top Five List in Oncology, as part of the ongoing Choosing Wisely® campaign that brings together the American Board of Internal Medicine (ABIM) Foundation, ASCO, and other medical specialty organizations. Cancer.Net provides...
ASCO Teams Up with the GetWell Network to Provide More Patients With Education Resources
Through a new initiative and partnership with the GetWell Network, ASCO has begun to offer patient education content from its patient information website, Cancer.Net, to patients treated at hospitals within the GetWell Network community. The GetWell Network provides tools to hospitals to help...
International Cancer Corps Provides Valuable First-Time Volunteer Experience
Even as oncologists try to tackle the changing landscape of health care in the United States, many realize that both physicians and patients in this country are still in a better position than those fighting cancer abroad in low- and middle-income countries. In 2009, ASCO joined with Health...
SIDEBAR: IMWG Recommendations
The International Myeloma Working Group (IMWG) recommends intravenous zoledronic acid as first-line therapy and intravenous pamidronate as second-line therapy for all patients being treated for multiple myeloma, regardless of imaging findings.1 These drugs are given monthly for 2 years and can be...
Options for Management of Bone Health in Patients With Multiple Myeloma
Bone health is critical in patients with multiple myeloma, since up to 85% will suffer bone damage. Options for management include two FDA-approved bisphosphonates—pamidronate and zoledronic acid—and possibly the RANK-L inhibitor denosumab (Xgeva, investigational use). Importance of Supportive ...
Take-Home Messages From the NCCN Hematologic Malignancies Conference
As the National Comprehensive Cancer Network (NCCN) 8th Annual Congress: Hematologic Malignancies was drawing to a close, The ASCO Post spoke with Andrew D. Zelenetz, MD, PhD, about the themes of the meeting and the take-home messages for attendees and for our readers. Dr. Zelenetz is Vice Chair...
Expert Point of View: Andrew D. Zelenetz, MD, PhD
In the past, we considered multiple myeloma the poor sibling among lymphoid malignancies. We have seen an amazing amount of change in this field, and Dr. Anderson and colleagues have contributed to that progress. But despite the progress, most patients still relapse,” noted Andrew D. Zelenetz, MD,...
New Strategies for Relapsed/Refractory Multiple Myeloma Explored
Although upfront therapy can achieve remission in multiple myeloma, most patients will ultimately relapse. Newer targeted therapies and genomic analysis are moving the management of relapsed/refractory multiple myeloma forward, according to Kenneth C. Anderson, MD, Director, Jerome Lipper Multiple...
Roswell Park Cancer Institute, University of Pittsburgh Cancer Institute, Receive $11 Million Spore Grant for Joint Research in Ovarian Cancer
The National Cancer Institute has awarded more than $11 million in funding to Roswell Park Cancer Institute (RPCI), in collaboration with the University of Pittsburgh Cancer Institute (UPCI), to begin an aggressive, multipronged search into preventing and treating ovarian cancer. Distributed over 5 ...
Gastric Cancer Foundation Announces Research Partnership With AGA
The Gastric Cancer Foundation recently announced the formation of a research partnership with the American Gastroenterological Association (AGA) and a confirmed timeline for awarding newly funded research grants for upper gastrointestinal tract cancers. Wayne Feinstein, Chairman of the Board of...
The AVEX Trial
As reported in The Lancet Oncology by Cunningham and colleagues and reviewed in this issue of The ASCO Post, the AVEX trial was an open-label randomized phase III trial limited to patients over the age of 70 years with previously untreated, unresectable metastatic colorectal cancer who were not...
Bevacizumab/Capecitabine Improves Progression-Free Survival in Older Patients With Treatment-Naive Metastatic Colorectal Cancer
Elderly patients are often underrepresented in clinical trials of metastatic colorectal cancer. In the phase III AVEX trial reported in The Lancet Oncology,1 David Cunningham, MD, of Royal Marsden Hospital in London and colleagues assessed the addition of bevacizumab (Avastin) to capecitabine in...
Expert Point of View: Josep Tabernero, MD, PhD and Eric Van Cutsem, MD, PhD
At the European Cancer Congress (ECC), Josep Tabernero, MD, PhD, Head of the Medical Oncology Department at Vall d’Hebron University in Barcelona, Spain, noted that the ASPECCT study asks a “reasonable question about the efficacy and safety of the two clinically approved anti-EGFR antibodies” and...
Panitumumab vs Cetuximab in Chemorefractory Colorectal Cancer: Survival Benefits Comparable
For the treatment of wild-type KRAS metastatic colorectal cancer in previously treated patients, a head-to-head comparison of the two antibodies—cetuximab (Erbitux) and panitumumab (Vectibix)—that target the epidermal growth factor receptor (EGFR) concluded that they convey similar overall survival ...
Expert Point of View: Alberto Sobrero, MD
Alberto Sobrero, MD, who discussed the VICTOR trial at the European Cancer Congress, said that at this point, adjuvant trials may be unethical, if the findings of multiple observational studies are to be trusted. Apparently, Dr. Sobrero is a believer: He introduced his remarks at the ECC session by ...
Aspirin Protects Against Colorectal Cancer Recurrence in PIK3CA-Mutant Tumors
At the 2013 European Cancer Congress, two investigative teams attempted to explain how aspirin may protect against colorectal cancer recurrences, with one study showing PIK3CA mutations associated with protection from aspirin, but not a COX-2 inhibitor, and the other study implicating HLA class I...
ESMO President Martine Piccart, MD, PhD, on the Importance of Diagnostics in Move From Stratified to Personalized Care
We are now living in an era of stratified oncology. The European Cancer Congress (ECC) 2013 held recently in Amsterdam provided many opportunities to attendees, including chance for discussions with basic and translational scientists, researchers, pathologists, and clinicians, as well as time for...
SIDEBAR: Highlighted Abstracts to Watch in San Antonio
S1-01. Piccart-Gebhart M, Holmes AP, de Azambuja E, et al: The association between event-free survival and pathological complete response to neoadjuvant lapatinib, trastuzumab or their combination in HER2-positive breast cancer. Survival follow-up analysis of the NeoALTTO study (BIG 1-06) S1-02....
Program Co-Directors Highlight Abstracts of Interest for the Upcoming 2013 San Antonio Breast Cancer Symposium
The Co-Directors of the 2013 CTRC-AACR San Antonio Breast Cancer Symposium, which will be held December 10–14, 2013, have highlighted what they consider to be the most important abstracts to be presented at the Symposium. In a telebriefing in advance of the December meeting, C. Kent Osborne, MD,...
Expert Point of View: Steven J. O'Day, MD
This is a provocative and compelling study. I applaud Dr. Herman and his team. The take-home message was beautifully articulated,” said presscast moderator Steven J. O’Day, MD, Director of Clinical Research at the Beverly Hills Cancer Center and Adjunct Member of the John Wayne Cancer Institute in...
Women Undergoing Mammography Fail to Understand Breast Cancer Risk
More than 90% of women undergoing mammography screening could not give an accurate estimate of their personal risk of developing breast cancer, according to results of a large survey reported at the 2013 ASCO Breast Cancer Symposium and featured in a premeeting presscast. The survey showed that a...
Optimizing Anti-HER2 Treatment for Metastatic Breast Cancer in 2013
The good news about HER2-positive breast cancer is that recurrent disease is plummeting, owing to the impact of adjuvant trastuzumab [Herceptin]. Hopefully, first-line metastatic treatment is becoming a thing of the past,” said Harold Burstein, MD, PhD, of Dana-Farber Cancer Institute, Boston....
The Devastating Impact of Sequestration on Medical Research
The primacy of science and the overwhelming belief in medical research by the American people has sustained the research community and improved quality of life roughly since the turn of the 20th century. Almost without exception, the American people have voted for politicians who promise improved...
The Scientific Perils of Sequestration
We are just 7 months into the $1 trillion in automatic federal budget spending cuts known as sequestration, and the impact on scientists in all areas of research is already so great, some say its full effects may be irreversible. The ASCO Post recently interviewed ASCO President Clifford A. Hudis, ...
Expert Point of View: Paul Baas, MD, PhD
“It is very good to have a drug for patients who are smokers and former smokers. The antibody works in both adenocarcinoma and squamous cell carcinoma, and is already very active in phase I with very few side effects. This is such impressive data that [perhaps] we could leap directly to a phase III ...
Novel Anti–PD-L1 Antibody Produces Durable Responses in Metastatic NSCLC, Smokers Included
The engineered monoclonal antibody MPDL3280A achieved encouraging and durable responses in a phase I study in metastatic non–small cell lung cancer (NSCLC) in both smokers and nonsmokers, as well as in cancers of squamous and adenocarcinoma histology. Responses were more robust in smokers than...
FDA Approves Obinutuzumab for Chronic Lymphocytic Leukemia
The U.S. Food and Drug Administration (FDA) has approved obinutuzumab (Gazyva) for use in combination with chlorambucil (Leukeran) to treat patients with previously untreated chronic lymphocytic leukemia (CLL). Obinutuzumab is the first drug with Breakthrough Therapy designation to receive FDA...
COMMENTARY: Choosing Wisely: Good Care With Efficiency
Is more care better care? It is often said, by Americans, that the United States has the best care in the world. However, there are many population-based statistics that do not support that humble opinion. We certainly spend more money than any other nation by far. In fact, we may spend more money ...
ASCO's 2013 Top Five List in Oncology for Choosing Wisely Campaign
ASCO recognizes the importance of evidence-based cancer care and making wise choices in the diagnosis and management of patients with cancer. After careful consideration by experienced oncologists, ASCO annually highlights five categories of tests, procedures and/or treatments annually whose common ...
Patient Assistance Programs Provide Psychosocial but Not Practical Help
“Patients with breast cancer who connect to relevant patient assistance programs receive useful informational and psychosocial but not practical help,” concluded Nina A. Bickell, MD, MPH, of Mount Sinai School of Medicine in New York, and colleagues who conducted a randomized trial among 374 women...
Impact of Hormone Replacement Therapy on Breast Cancer Risk Varies by Race, Weight, and Breast Density
The impact of hormone replacement therapy on breast cancer risk varies according to the patient’s to race/ethnicity, body mass index, and breast density. An analysis of 1,642,824 screening mammograms with 9,300 breast cancer cases in postmenopausal women aged 45 years or older found that hormone...
Variations in Risk Factors Suggest Distinct Etiology for Inflammatory Breast Cancer
“Varying risk factor associations between inflammatory and noninflammatory breast cancer suggest a distinct etiology for [inflammatory] breast cancer,” according to a study in the Journal of the National Cancer Institute. High body mass index was shown to increase risk of inflammatory breast cancer ...
The Power of Human Attachment
For those patients with cancer who may be single, widowed, separated, or divorced, those for whom a natural social support system may be weak, the role of the cancer support group should not be overlooked. In leading a previous trial of supportive-expressive group therapy as a key pathway to foster ...
SIDEBAR: Expect Questions About Support Systems for Unmarried Patients
The study finding that unmarried patients with cancer “are at significantly higher risk of presentation with metastatic cancer, undertreatment, and death resulting from their cancer,” generated a lot of comments from colleagues, family members, and patients, the study’s lead author Ayal A. Aizer,...
'Clear and Consistent Protective Effect of Marriage' Found in Patients With 10 Most Clinically Significant Cancers
A clear and consistent protective effect of marriage among patients harboring one of the 10 most clinically significant malignancies affecting Americans” was found in a study analyzing Surveillance, Epidemiology, and End Results (SEE) data for 734,889 patients diagnosed with lung, colorectal,...
Decoding Annie Parker: Hunting the Breast Cancer Gene
Based on true events, Decoding Annie Parker follows the parallel stories of two women obsessed with finding a genetic link to breast cancer. And from the film’s opening frame until the closing credits roll, the absorbing tale never allows your mind to wander. Attempting to Elude Fate One woman is...
CancerCare Launches New Edition of Financial Resource Guide for People With Cancer
CancerCare recently announced the launch of a new edition of A Helping Hand: The Resource Guide for People With Cancer, Financial Edition, a reference guide to assist patients with cancer and their families in navigating the financial resources available to them. A Helping Hand is a comprehensive...
Omega-3
Common Name: Polyunsaturated fatty acids (PUFAs) Brand Names: Omegaven, Max-EPA The use of dietary supplements by patients with cancer has increased significantly over the past 2 decades despite insufficient evidence of safety and effectiveness. Finding reliable sources of information about...
Having Bladder Cancer Has Taught Me Important Life Lessons
I think one of the most frightening—and embarrassing—things that can happen to an adult is losing control of your bladder and wetting the bed. When that happened to me in the spring of 2012 while I was on a camping trip with my wife Kimberly and our two teenage daughters, I knew something was very...
SIDEBAR: Five Proposals for the FDA
At a forum convened by Friends of Cancer Research in September 2013, a panel of experts presented five proposals outlining how sponsors and FDA may be able to improve and expedite the process for the codevelopment and review of a companion diagnostic designed for use with a drug that has received...
FDA Hears Proposals on Codevelopment of Companion Diagnostics for Breakthrough Therapies
A companion diagnostic developed for use with a drug that has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) should automatically be eligible for priority review, according to an expert panel that presented this proposal and four others to the FDA in...
NIH Awards $17 Million in Grants to Augment Genomics Research in Africa
The National Institutes of Health has awarded 10 new grants totaling up to $17 million over the next 4 years to support genomics research in Africa, as part of the Human Heredity and Health in Africa (H3Africa) program. This set of grants is the second disbursement of H3Africa awards and brings the ...
FDA Approves Transducer Array Layout System for Use in Patients With Recurrent Glioblastoma Multiforme
Novocure recently announced that it has received FDA approval for its NovoTAL (Transducer Array Layout) System through a Premarket Approval supplement. The NovoTAL System allows certified physicians to use the individual magnetic resonance imaging data of recurrent glioblastoma multiforme patients...
IOM Presents 2013 Lienhard Award to Leader of Smoking Cessation and Tobacco Prevention Efforts
The Institute of Medicine has (IOM) presented the 2013 Gustav O. Lienhard Award to Steven A. Schroeder, MD, whose pioneering efforts to control tobacco use have helped save millions from premature, smoking-related deaths. The award also recognizes Dr. Schroeder’s leadership in general medicine as...
Focus on the Texas Society of Clinical Oncology
The second largest state in the nation (after Alaska), Texas covers a total area of 268,581 square miles and has a diverse population of over 26 million people. In 1987, the Texas Society of Medical Oncology, now the Texas Society of Clinical Oncology (TxSCO), was formed to address the oncology...
Yoga to Manage Sleep Disruption in Cancer Survivors: A Low-Risk Intervention With High Potential for Benefit
Impaired sleep quality is a concerning problem for many patients with cancer, and pharmacologic treatments come with many negative effects. Several small studies indicate that yoga improves persistent fatigue, sleep disturbance, anxiety, and quality of life, in addition to reducing the need for...
